Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof
AssigneeSignature Therapeutics, Inc.
InventorsThomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.
Claims66
A composition comprising:
- an opioid prodrug comprising an opioid covalently bound to a promoiety comprising a GI enzyme-cleavable moiety, wherein cleavage of the GI enzyme-cleavable moiety by a GI enzyme mediates release of the opioid;
- and
- a GI enzyme inhibitor that interacts with the GI enzyme that mediates enzymatically-controlled release of the opioid from the opioid prodrug following ingestion of the composition.
A method of making a dose unit, the method comprising:
- combining in a dose unit:
- an opioid prodrug comprising an opioid covalently bound to a promoiety cleavable by a GI enzyme, wherein cleavage of the promoiety by the GI enzyme mediates release of the opioid from the opioid prodrug;
- and
- a GI enzyme inhibitor that interacts with the enzyme that mediates enzymatically-controlled release of the opioid from the opioid prodrug;
- wherein the opioid prodrug and GI enzyme inhibitor are present in the dose unit in an amount effective to attenuate release of the opioid from the opioid prodrug such that ingestion of multiples of dose units by a patient does not provide a proportional release of opioid.
A method for identifying an opioid prodrug and a GI enzyme inhibitor suitable for formulation in a dose unit, the method comprising:
- combining an opioid prodrug, a GI enzyme inhibitor, and GI enzyme in a reaction mixture, wherein the opioid prodrug comprises an opioid covalently bound to a promoiety comprising a GI enzyme-cleavable moiety, wherein cleavage of the GI enzyme-cleavable moiety by the enzyme mediates release of the opioid;
- and
- detecting opioid prodrug conversion,
- wherein a decrease in opioid prodrug conversion in the presence of the GI enzyme inhibitor as compared to opioid prodrug conversion in the absence of the GI enzyme inhibitor indicates the opioid prodrug and GI enzyme inhibitor are suitable for formulation in a dose unit.
A method for identifying an opioid prodrug and a GI enzyme inhibitor suitable for formulation in a dose unit, the method comprising:
- administering to an animal an opioid prodrug and a GI enzyme inhibitor, wherein the opioid prodrug comprises an opioid covalently bound to a promoiety comprising a GI enzyme-cleavable moiety, wherein cleavage of the GI enzyme-cleavable moiety by the enzyme mediates release of the opioid;
- and
- detecting opioid prodrug conversion, wherein a decrease in opioid conversion in the presence of the GI enzyme inhibitor as compared to opioid conversion in the absence of the GI enzyme inhibitor indicates the opioid prodrug and GI enzyme inhibitor are suitable for formulation in a dose unit.
A method for identifying an opioid prodrug and a GI enzyme inhibitor suitable for formulation in a dose unit, the method comprising:
- administering to an animal tissue an opioid prodrug and a GI enzyme inhibitor, wherein the opioid prodrug comprises a opioid covalently bound to a promoiety comprising a GI enzyme-cleavable moiety, wherein cleavage of the GI enzyme-cleavable moiety by the enzyme mediates release of the opioid;
- and
- detecting opioid prodrug conversion, wherein a decrease in opioid prodrug conversion in the presence of the GI enzyme inhibitor as compared to opioid prodrug conversion in the absence of the GI enzyme inhibitor indicates the opioid prodrug and GI enzyme inhibitor are suitable for formulation in a dose unit.
Dependencies are inferred from the claim text.